Aim: In this study, PLGA nanoparticles (PNPs) emulsified in Pluronic F127 (F127)/Lecithin (LEC) were designed to load Itacitinib (ITA), a selective JAK1 inhibitor, for targeting human monocytes.Materials & methods: The physicochemical characteristics of empty and ITA-loaded F127/LEC PNPs were analyzed. The binding and internalization of NPs in leukocytes were evaluated. The effect of NPs on monocyte activation and JAK1 inhibition was assessed.Results: F127/LEC PNPs were selectively bound and internalized by monocytes, sparing other leukocytes. ITA-F127/LEC PNPs significantly dampened monocyte activation. They also inhibited the monocyte's ability to promote T-cell proliferation and inhibited proinflammatory cytokine production.Conclusion: ITA-loaded F127/LEC PNPs showed potential for monocyte-targeted therapy, offering new avenues for disease treatment.
Aim: To investigate the effect of surfactant type on curcumin-loaded (CUR) PLGA nanoparticles (NPs) to modulate monocyte functions. Materials & methods: The nanoprecipitation method was used, and PLGA NPs were designed using Pluronic F127 (F127) and/or lecithin (LEC) as surfactants. Results: The Z-average of the NPs was 0.128 MPa, they were stable during storage at 4°C, ζ-potential ∼-40 mV, polydispersity index 94%. PLGA-LEC/F127 NPs showed favorable physicochemical and nanomechanical properties. These NPs were bound and internalized mainly by monocytes, suppressed monocyte-induced reactive oxygen species production, and decreased the ability of monocytes to modulate T-cell proliferation. Conclusion: These results demonstrate the potential of these NPs for targeted therapy.
Localized treatment has emerged as an excellent alternative to minimize the side effects associated with the systemic dispersion of therapeutic agents, which can damage healthy tissues. Injectable hydrogels offer a promising solution because they can encapsulate and release therapeutic agents in a controlled manner. In this context, this study focuses on the development and characterization of an injectable hydrogel based on carboxymethyl chitosan (CMCh) and oxidized agarose (OA), in which chemical crosslinking through imine bond formation avoids the use of external crosslinking agents. Several polymer ratios were evaluated to obtain hydrogels (OA:CMCh), and stable gels were formed at physiological temperatures in all cases. The hydrogels were injectable through a 21 G needle with forces below 30 N, formed porous structures, and exhibited a self-healing capacity after 48 h. Additionally, the hydrogels displayed compressive strengths ranging from 26 to 71 kPa and elastic moduli similar to those of human tissues (6–20 kPa). Swelling percentages of up to 3090% were achieved owing to the high hydrophilicity of CMCh and OA, and strong chemical crosslinking maintained the gel stability for two weeks with low mass loss rates (<21%). Furthermore, polymer ratio variation and storage at 4 °C were observed to affect the hydrogel characteristics, allowing for property modulation according to the application needs. These results indicate that the proposed polymeric combination enables the formation of hydrogels with the potential for localized drug delivery.